Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
39.41
+0.04 (0.10%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Immunovant Market Cap
Immunovant has a market cap or net worth of $8.13 billion as of July 24, 2026. Its market cap has increased by 158.56% in one year.
Market Cap
8.13B
Enterprise Value
7.23B
1-Year Change
158.56%
Ranking
Category
Stock Price
$39.41
ChartMarket Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $8.13B, an increase of 6,440.15%. That is a compound annual growth rate of 80.25%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 24, 2026 | 8.09B | 57.05% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ionis Pharmaceuticals | 9.23B |
| Kymera Therapeutics | 9.08B |
| Praxis Precision Medicines | 8.99B |
| Crinetics Pharmaceuticals | 8.82B |
| Spyre Therapeutics | 8.79B |
| Protagonist Therapeutics | 8.71B |
| Vaxcyte | 8.03B |
| TG Therapeutics | 7.87B |